Literature DB >> 11812089

Prognostic value of positron emission tomography using F-18-fluorodeoxyglucose in patients with cervical cancer undergoing radiotherapy.

Yuji Nakamoto1, Avraham Eisbruch, Eric D Achtyes, Yoshifumi Sugawara, Kevin R Reynolds, Carolyn M Johnston, Richard L Wahl.   

Abstract

OBJECTIVE: The purpose of this study was to determine whether positron emission tomography (PET) using F-18-fluorodeoxyglucose (FDG) before and after radiotherapy would predict whether local control of cervical cancer had been achieved.
METHODS: FDG-PET scans were performed prior to therapy and at a mean of 4.6 months after radiation in 20 patients (pts) with histologically proven uterine cervical cancer who were undergoing a "curative" course of radiation therapy. FDG uptake was interpreted visually by two readers using a 5-point grading system (0 = normal, 1 = probably normal, 2 = equivocal, 3 = probably abnormal, and 4 = definitely abnormal). The standardized uptake values corrected by lean body mass (SUL) were calculated for suspicious areas. The percentage of residual activity (%RA) for the posttherapy SUL was also evaluated as a percentage of the pretherapy SUL.
RESULTS: At baseline before irradiation, 17 of 20 (85.0%) primary tumors were detected. Following irradiation, no or low (grade 0-2) uptake was observed in 9 pts, and none of these had local recurrence. Among the remaining 11 pts with grade 3 or 4 uptake, the correct diagnosis was made for 5 pts with active tumor; SULs (mean +/- SD = 4.17 +/- 2.52) and %RAs (57.9 +/- 16.8). Six patients without active tumor showed relatively low SULs (2.67 +/- 0.69) and %RAs (43.0 +/- 18.3). No significant differences were observed between the recurrent and nonrecurrent groups for these parameters. Overall, sensitivity, specificity, and accuracy were 100, 60, and 70%, respectively.
CONCLUSION: These preliminary data indicate that FDG-PET is a sensitive tool for detecting active cervical cancer after radiation, however, the method, without anatomic correlation had suboptimal specificity. ©2002 Elsevier Science.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11812089     DOI: 10.1006/gyno.2001.6504

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  6 in total

1.  Performance of FDG-PET/CT for diagnosis of recurrent uterine cervical cancer.

Authors:  Kazuhiro Kitajima; Koji Murakami; Erena Yamasaki; Yasushi Domeki; Yasushi Kaji; Kazuro Sugimura
Journal:  Eur Radiol       Date:  2008-04-19       Impact factor: 5.315

2.  Monitoring the neoadjuvant therapy response in gynecological cancer patients using FDG PET.

Authors:  Yoshihiro Nishiyama; Yuka Yamamoto; Kenji Kanenishi; Masami Ohno; Toshiyuki Hata; Yoshio Kushida; Reiji Haba; Motoomi Ohkawa
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-10-18       Impact factor: 9.236

3.  Imaging uterine cervical cancer with FDG-PET/CT: direct comparison with PET.

Authors:  Mitsuaki Tatsumi; Christian Cohade; Robert E Bristow; Richard L Wahl
Journal:  Mol Imaging Biol       Date:  2009-05-12       Impact factor: 3.488

4.  Usefulness of F-18 FDG PET/CT in Assessment of Recurrence of Cervical Cancer After Treatment.

Authors:  Minkyung Lee; Yukyung Lee; Kyung Hoon Hwang; Wonsick Choe; Chan Yong Park
Journal:  Nucl Med Mol Imaging       Date:  2011-01-28

5.  [18F]FDG PET as a substitute for second-look laparotomy in patients with advanced ovarian carcinoma.

Authors:  Sungeun Kim; June-Key Chung; Soon-Beom Kang; Moon-Hong Kim; Jae Min Jeong; Dong Soo Lee; Myung Chul Lee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-02       Impact factor: 9.236

Review 6.  Positron emission tomography alone, positron emission tomography-computed tomography and computed tomography in diagnosing recurrent cervical carcinoma: a systematic review and meta-analysis.

Authors:  Yi Xiao; Jia Wei; Yicheng Zhang; Weining Xiong
Journal:  Arch Med Sci       Date:  2014-05-13       Impact factor: 3.318

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.